5/17/2023 0 Comments Loxone 400![]() When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. At this dosage, the urinary concentration exceeds the MICs for most urinary pathogens susceptible to norfloxacin, even when the creatinine clearance is less than 10 mL/min/1.73 m². In patients with a creatinine clearance rate of 30 mL/min/1.73 m² or less, the recommended dosage is one 400-mg tablet once daily for the duration given above. Loxone-400 may be used for the treatment of urinary tract infections in patients with renal insufficiency. Uncomplicated UTI's due to other indicated organisms The recommended daily dose of Loxone-400 is as described in the following chart: Patients receiving Loxone-400 should be well hydrated (see PRECAUTIONS). Tablets Loxone-400 should be taken with a glass of water. Multivitamins, other products containing iron or zinc, antacids containing magnesium and aluminum, sucralfate, or Videx® (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should not be taken within 2 hours of administration of norfloxacin. Tablets Loxone-400 should be taken at least one hour before or at least two hours after a meal or ingestion of milk and/or other dairy products. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Loxone-400 and other antibacterial drugs, Loxone-400 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Repeat culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agents but also on the possible emergence of bacterial resistance. Therapy with norfloxacin may be initiated before results of these tests are known once results become available, appropriate therapy should be given. Penicillinase production should have no effect on norfloxacin activity.Īppropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to norfloxacin. ![]() (See DOSAGE AND ADMINISTRATION for appropriate dosing instructions.) ![]() Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. Sexually transmitted diseases (see WARNINGS) ![]() Uncomplicated urinary tract infections (including cystitis) due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus, Citrobacter freundii 1, Enterobacter aerogenes 1, Enterobacter cloacae 1, Proteus vulgaris 1, Staphylococcus aureus1, or Streptococcus agalactiae 1.īecause fluoroquinolones, including Loxone-400, have been associated with serious adverse reactions (see WARNINGS), and for some patients uncomplicated urinary tract infection is self-limiting, reserve Loxone-400 for treatment of uncomplicated urinary tract infections (including cystitis) in patients who have no alternative treatment options.Ĭomplicated urinary tract infections due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Serratia marcescens 1. Loxone-400 is indicated for the treatment of adults with the following infections caused by susceptible strains of the designated microorganisms: Urinary Tract Infections ![]()
0 Comments
Leave a Reply. |